Your browser doesn't support javascript.
Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2021.
Stehmann, Christiane; Senesi, Matteo; Sarros, Shannon; McGlade, Amelia; Lewis, Victoria; Simpson, Marion; Klug, Genevieve; McLean, Catriona; Masters, Colin L; Collins, Steven.
  • Stehmann C; The Florey Institute, The University of Melbourne, Victoria, 3010, Australia.
  • Senesi M; Department of Medicine, The University of Melbourne, Victoria, 3010, Australia.
  • Sarros S; The Florey Institute, The University of Melbourne, Victoria, 3010, Australia.
  • McGlade A; The Florey Institute, The University of Melbourne, Victoria, 3010, Australia.
  • Lewis V; Department of Medicine, The University of Melbourne, Victoria, 3010, Australia.
  • Simpson M; The Florey Institute, The University of Melbourne, Victoria, 3010, Australia.
  • Klug G; The Florey Institute, The University of Melbourne, Victoria, 3010, Australia.
  • McLean C; The Florey Institute, The University of Melbourne, Victoria, 3010, Australia.
  • Masters CL; The Alfred Hospital, Department of Anatomical Pathology, 55 Commercial Rd, Melbourne Vic 3004 Australia.
  • Collins S; The Florey Institute, The University of Melbourne, Victoria, 3010, Australia.
Commun Dis Intell (2018) ; 462022 Aug 18.
Article in English | MEDLINE | ID: covidwho-1994942
ABSTRACT
Nationwide surveillance of Creutzfeldt-Jakob disease (CJD) and other human prion diseases is performed by the Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR). National surveillance encompasses the period since 1 January 1970, with prospective surveillance occurring from 1 October 1993. Over this prospective surveillance period, considerable developments have occurred in pre-mortem diagnostics; in the delineation of new disease subtypes; and in a heightened awareness of prion diseases in healthcare settings. Surveillance practices of the ANCJDR have evolved and adapted accordingly. This report summarises the activities of the ANCJDR during 2021. Since the ANCJDR began offering diagnostic cerebrospinal fluid (CSF) 14-3-3 protein testing in Australia in September 1997, the annual number of referrals has steadily increased. In 2021, a total of 548 domestic CSF specimens were referred for 14-3-3 protein testing; 73 persons with suspected human prion disease were formally added to the national register. As of 31 December 2021, just over half of the 73 suspect case notifications (37/73) remain classified as 'incomplete'; 17 cases were classified as 'definite' and 13 as 'probable' prion disease; six cases were excluded through either detailed clinical follow-up (two cases) or neuropathological examination (four cases). For 2021, sixty-four percent of all suspected human-prion-disease-related deaths in Australia underwent neuropathological examination. No cases of variant or iatrogenic CJD were identified. The SARS-CoV-2 pandemic did not affect prion disease surveillance outcomes in Australia.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Creutzfeldt-Jakob Syndrome / Prion Diseases / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Variants Limits: Humans Country/Region as subject: Oceania Language: English Year: 2022 Document Type: Article Affiliation country: Cdi.2022.46.53

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Creutzfeldt-Jakob Syndrome / Prion Diseases / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Variants Limits: Humans Country/Region as subject: Oceania Language: English Year: 2022 Document Type: Article Affiliation country: Cdi.2022.46.53